Replimune Group (NASDAQ:REPL) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Replimune Group (NASDAQ:REPL) in a research note released on Friday, MarketBeat Ratings reports. The firm issued an overweight rating on the stock.

Several other research analysts have also recently issued reports on REPL. JPMorgan Chase & Co. increased their target price on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Piper Sandler upped their price target on shares of Replimune Group from $14.00 to $22.00 and gave the stock an “overweight” rating in a research report on Monday, June 2nd. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Replimune Group presently has an average rating of “Buy” and a consensus price target of $20.83.

Replimune Group Trading Down 2.3%

REPL opened at $9.27 on Friday. The stock’s fifty day moving average is $8.83 and its two-hundred day moving average is $10.79. The company has a market capitalization of $714.62 million, a P/E ratio of -3.02 and a beta of 0.63. Replimune Group has a 52 week low of $6.44 and a 52 week high of $17.00. The company has a quick ratio of 7.95, a current ratio of 7.95 and a debt-to-equity ratio of 0.17.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period last year, the firm posted ($0.25) earnings per share. Analysts forecast that Replimune Group will post -2.97 earnings per share for the current year.

Insider Activity at Replimune Group

In related news, CAO Andrew Schwendenman sold 3,287 shares of the business’s stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total transaction of $26,460.35. Following the completion of the transaction, the chief accounting officer now owns 68,284 shares in the company, valued at $549,686.20. The trade was a 4.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Konstantinos Xynos sold 7,952 shares of Replimune Group stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $64,093.12. Following the completion of the transaction, the insider now directly owns 146,933 shares in the company, valued at $1,184,279.98. This represents a 5.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 74,907 shares of company stock valued at $603,655 over the last quarter. 8.80% of the stock is owned by corporate insiders.

Institutional Trading of Replimune Group

A number of institutional investors have recently made changes to their positions in REPL. Rhumbline Advisers raised its stake in Replimune Group by 8.3% in the fourth quarter. Rhumbline Advisers now owns 95,465 shares of the company’s stock valued at $1,156,000 after buying an additional 7,317 shares during the last quarter. New York State Common Retirement Fund grew its stake in shares of Replimune Group by 260.8% during the fourth quarter. New York State Common Retirement Fund now owns 43,204 shares of the company’s stock worth $523,000 after acquiring an additional 31,231 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Replimune Group by 7.3% during the fourth quarter. Bank of New York Mellon Corp now owns 174,518 shares of the company’s stock valued at $2,113,000 after acquiring an additional 11,893 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Replimune Group by 4.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 508,398 shares of the company’s stock valued at $6,157,000 after acquiring an additional 23,601 shares in the last quarter. Finally, Victory Capital Management Inc. purchased a new position in shares of Replimune Group in the 4th quarter valued at approximately $543,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.